<DOC>
	<DOCNO>NCT00274976</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , alemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . PURPOSE : This phase II trial study well give alemtuzumab injection work treat patient advance chronic lymphocytic leukemia respond previous fludarabine .</brief_summary>
	<brief_title>Alemtuzumab Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond Previous Fludarabine</brief_title>
	<detailed_description>OBJECTIVES : - Compare safety efficacy subcutaneous alemtuzumab v intravenous alemtuzumab patient fludarabine-refractory advanced chronic lymphocytic leukemia . - Determine response patient high-risk genetic abnormality ( unmutated immunoglobulin variable heavy-chain [ IgVH ] status , del [ 17p ] , del [ 11q ] ) treat subcutaneous alemtuzumab progression fludarabine . OUTLINE : This multicenter study . Patients receive alemtuzumab IV , follow 1 week later alemtuzumab subcutaneously weekly 12 week . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis previously treat advanced chronic lymphocytic leukemia ( CLL ) Fludarabinerefractory disease Requires treatment PATIENT CHARACTERISTICS : Life expectancy 6 month ECOG 02 No severe organ dysfunction No concomitant previous neoplasms No autoimmune hemolytic anemia thrombocytopenia PRIOR CONCURRENT THERAPY : See Disease Characteristics Up 5 prior chemotherapy regimen allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>